COMMUNIQUÉS West-GlobeNewswire

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.
03/07/2018
FIT Biotech Oy Press Release July 3 rd 2018, 10.00 EET FIT Biotech webcasts the company half-year financial report on September 6 th 2018, at 10.00 AM. FIT Biotech's half-year financial report will be webcasted on [...]
Shire plc : Rule 2.9 Announcement
03/07/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 3 July 2018 Shire [...]
Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors
03/07/2018
NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has [...]
FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.
03/07/2018
FIT Biotech Oy Press Release July 3 rd 2018, 08.30 EET FIT Biotech webcasts the company half-year financial report on September 6 th 2018, at 10.00 AM. FIT Biotech's half-year financial report will be webcasted on [...]
NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS
03/07/2018
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFN alpha KINOID IN THE TREATMENT OF LUPUS WHICH ALLOWS TO PROCEED WITH THE CLINICAL DEVELOPMENT INTO PHASE III THE [...]
NÉOVACS ANNONCE LES RÉSULTATS DE L'ÉTUDE DE PHASE IIB AVEC L'IFNalpha KINOÏDE POUR LE TRAITEMENT DU LUPUS
03/07/2018
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ANNONCE LES RÉSULTATS DE L'ÉTUDE DE PHASE IIB AVEC L'IFNalpha KINOÏDE POUR LE TRAITEMENT DU LUPUS AUTORISANT LA POURSUITE DU DÉVELOPPEMENT [...]
iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer
03/07/2018
iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the [...]
Lexington Biosciences Announces Results of Annual General Meeting
03/07/2018
VANCOUVER, British Columbia, July 02, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, wishes to provide the [...]
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
02/07/2018
YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has [...]
Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures
02/07/2018
LAVAL, Québec, July 02, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ:ACST) (TSX-V:ACST), today announced the grant of stock options to its employees, executives and directors, and that [...]
Neuronetics, Inc., Maker of NeuroStar® Advanced Therapy, Announces Closing of Initial Public Offering and the Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
02/07/2018
MALVERN, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Neuronetics, Inc., a commercial-stage medical device company focused on designing, developing, and manufacturing products that improve the quality of life for patients who [...]
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/07/2018
EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it [...]
HMS Settles Litigation Related To 2010 Asset Purchase - Agreement Substantially Reduces 2017 Jury Award
02/07/2018
IRVING, Texas, July 02, 2018 (GLOBE NEWSWIRE) -- HMS Holdings Corp. (Nasdaq:HMSY) today announced that it has reached a settlement agreement in litigation pending in the Supreme Court of New York. The case related to [...]
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
02/07/2018
SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of [...]
NeoGenomics Schedules its Second Quarter Earnings Release for July 24, 2018
02/07/2018
FT. MYERS, Fla., July 02, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today that it plans to release its second quarter 2018 [...]
Zafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares
02/07/2018
BOSTON, July 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by [...]
TiGenix: Transparency Information
02/07/2018
PRESS RELEASE REGULATED INFORMATION Transparency Information Leuven (Belgium) - July 2, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of [...]
Align Technology to Announce Second Quarter 2018 Results on July 25, 2018
02/07/2018
SAN JOSE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq:ALGN) announced today that the Company will report second quarter 2018 financial results on Wednesday, July 25, 2018 after the close of [...]
OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer
02/07/2018
BATON ROUGE, La., July 02, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary [...]

Pages